Redmile Group LLC Has $17,975,000 Position in Oxford Immunotec Global PLC (OXFD)

Redmile Group LLC raised its stake in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,431,119 shares of the company’s stock after buying an additional 3,025 shares during the period. Oxford Immunotec Global PLC makes up approximately 1.4% of Redmile Group LLC’s investment portfolio, making the stock its 24th largest position. Redmile Group LLC owned approximately 6.33% of Oxford Immunotec Global PLC worth $17,975,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Bank of Montreal Can acquired a new position in shares of Oxford Immunotec Global PLC during the third quarter valued at $116,000. Wells Fargo & Company MN raised its position in shares of Oxford Immunotec Global PLC by 68.2% in the third quarter. Wells Fargo & Company MN now owns 21,195 shares of the company’s stock valued at $266,000 after buying an additional 8,593 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Oxford Immunotec Global PLC by 26.3% in the second quarter. Bank of New York Mellon Corp now owns 51,899 shares of the company’s stock valued at $467,000 after buying an additional 10,809 shares in the last quarter. Spark Investment Management LLC raised its position in shares of Oxford Immunotec Global PLC by 0.3% in the third quarter. Spark Investment Management LLC now owns 39,300 shares of the company’s stock valued at $493,000 after buying an additional 100 shares in the last quarter. Finally, Ardsley Advisory Partners acquired a new position in shares of Oxford Immunotec Global PLC during the third quarter valued at $502,000. Institutional investors and hedge funds own 78.71% of the company’s stock.

Institutional Ownership by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 13.45 on Friday. Oxford Immunotec Global PLC has a 12-month low of $7.73 and a 12-month high of $15.76. The firm has a 50-day moving average of $13.99 and a 200 day moving average of $12.77. The firm’s market capitalization is $304.00 million.

ILLEGAL ACTIVITY WARNING: “Redmile Group LLC Has $17,975,000 Position in Oxford Immunotec Global PLC (OXFD)” was first posted by sleekmoney and is the property of of sleekmoney. If you are reading this article on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this article can be viewed at http://sleekmoney.com/redmile-group-llc-has-17975000-position-in-oxford-immunotec-global-plc-oxfd/1656565.html.

Several equities analysts recently weighed in on OXFD shares. Zacks Investment Research lowered shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a report on Wednesday, November 30th. TheStreet lowered shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Monday, November 21st.

In other news, CEO Peter Wrighton-Smith sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $13.36, for a total value of $334,000.00. Following the completion of the transaction, the chief executive officer now directly owns 463,495 shares in the company, valued at approximately $6,192,293.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 95,000 shares of company stock valued at $1,384,494 over the last 90 days. Corporate insiders own 7.58% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

5 Day Chart for NASDAQ:OXFD

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/redmile-group-llc-has-17975000-position-in-oxford-immunotec-global-plc-oxfd/1656565.html

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *